Development and License Agreements (Details Narrative) - USD ($)			1 Months Ended							3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2022	Oct. 15, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Sep. 30, 2019	Jul. 31, 2019	Nov. 30, 2018	Dec. 31, 2016	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2019	Jun. 30, 2020	Mar. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and license agreements description												The academic COMBACTE-NET consortium partners initially pay for all costs incurred at EU clinical sites and subsequently bills the Company for 25% of such costs. Specifically, we are billed for 25% of eligible costs during the entire fiscal year six to seven months following the fiscal year. The work at these sites is performed entirely by third-party subcontractors. As such, we reimburse the 25% at the passed-through invoice amounts. There is no reimbursement for costs incurred at non-EU sites.
Research and development expense										$ 175,000	$ 6,118,000	$ 10,374,000	$ 18,916,000
Liabilities			$ 38,927,000							18,336,000		18,336,000		$ 38,927,000
Gain or loss on disposition												0
License revenue										417,000	399,000	21,146,000	1,878,000
License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue												19,602,000
Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of award			7,600,000					$ 7,500,000	$ 2,900,000
Award, upfront payment received									$ 200,000
Additional amount of award			150,000
License revenue										400,000	100,000	1,300,000	700,000
Grants Foundation Grant Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized										0	400,000	200,000	600,000
Grants Foundation Grant Agreement [Member] | Bill and Melinda Gates Foundation [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of compensation		$ 1,930,000
Upfront payment received		$ 1,930,000
Serum License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received						$ 15,000,000	$ 5,000,000
Liability revenue						$ 5,000,000
Fair value of net proceeds															$ 5,000,000.0
Fair value of gross proceeds															5,400,000
Issuance costs from equity allocation															$ 441,000
Deferred revenue from equity allocation										4,600,000		4,600,000
Contractual liability												19,600,000
Deferred revenue based on upfront payments												15,000,000.0
License fees												19,600,000
Deferred revenue based on upfront payments										15,000,000.0		15,000,000.0
Contractual liability										19,600,000		19,600,000
Serum License Agreement [Member] | License and Service [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual liability										14,500,000		14,500,000
Serum License Agreement [Member] | Development Support Services [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business development support services												79,000
Serum License Agreement [Member] | Research and Development Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual liability										892,000		892,000
Serum License Agreement [Member] | Manufacturing Rights Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Manufacturing rights option												4,100,000
Serum License Agreement [Member] | License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue										0		19,600,000
Kermode Licensing and Product Discovery Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized										0	$ 100,000	100,000	$ 500,000
Maximum additional payments entitled				$ 250,000								250,000
Gross transaction price	$ 1,000,000
Kermode Licensing and Product Discovery Agreement [Member] | Research and Development Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Nonrefundable upfront payment	500,000
Nonrefundable milestone payments	$ 500,000
Kermode Licensing and Product Discovery Agreement [Member] | License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received					$ 500,000
Non-EUSites [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense										700,000		1,400,000		5,500,000
EU Site [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense										$ 0		$ 2,300,000		3,800,000
Cost incurred percent										25.00%		25.00%
Gross expenses contributed services amount										$ 0		$ 1,700,000		2,900,000
Liabilities			$ 1,000,000.0							$ 600,000		600,000		1,000,000.0
Several Development Based Milestones [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Probable transaction price performance obligations																	$ 1,700,000
One Development Based Milestone in Progress [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of probable variable consideration																	$ 1,000,000.0
Amount of probable variable consideration																$ 1,000,000.0
Four Develpoment Based Milestones [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of variable consideration												3,800,000
Amount of total variable consideration														$ 3,900,000
Three Develpoment Based Milestones [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of variable consideration												$ 3,600,000
Restricted Stock [Member] | Serum License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted common stock issuance							801,820
Private placement, value							$ 10,000,000